Perhaps the darkest memory in modern pharmaceutical historyis that of the devastating effects of thalidomide exposure onfetal development. More than four decades later, thalidomidereemerged from the ashes as the prototype for a new proprietaryclass of drugs with broad pharmacologic effects and promisingantineoplastic activity, referred to collectively as immunomodulatorydrugs.
Thalidomide was first marketed in Europe in the late 1950s asa hypnotic and antiemetic for the treatment of morning sicknessduring pregnancy. Between 1956 and 1962, approximately 10,000children were born with severe physical deformities, or phocomelia,as a result of the drug's unrecognized teratogenic . . . [Full Text of this Article]
Source Information
From the H. Lee Moffitt Cancer Center and Research Institute, University of South Florida College of Medicine, Tampa.
This article has been cited by other articles:
Escoubet-Lozach, L., Lin, I-L., Jensen-Pergakes, K., Brady, H. A., Gandhi, A. K., Schafer, P. H., Muller, G. W., Worland, P. J., Chan, K. W.H., Verhelle, D.
(2009). Pomalidomide and Lenalidomide Induce p21WAF-1 Expression in Both Lymphoma and Multiple Myeloma through a LSD1-Mediated Epigenetic Mechanism. Cancer Res.
69: 7347-7356
[Abstract][Full Text]
Yamashita, T., Tamura, H., Satoh, C., Shinya, E., Takahashi, H., Chen, L., Kondo, A., Tsuji, T., Dan, K., Ogata, K.
(2009). Functional B7.2 and B7-H2 Molecules on Myeloma Cells Are Associated with a Growth Advantage. Clin. Cancer Res.
15: 770-777
[Abstract][Full Text]
Brenner, H., Gondos, A., Pulte, D.
(2009). Expected long-term survival of patients diagnosed with multiple myeloma in 2006-2010. haematol
94: 270-275
[Abstract][Full Text]
Previous
